Autonomix Medical Inc Stock Price, News & Analysis

Autonomix Medical (NASDAQ: AMIX) has achieved a important milestone by finalizing the design ('design lock') of its Application Specific Integrated Circuits (ASIC) microchip following successful in vivo preclinical and bench testing. The company has initiated manufacturing of the ASIC microchip for human use and is progressing toward submitting an Investigational Device Exemption (IDE).

The ASIC microchip is central to Autonomix's intellectual property portfolio, enabling the detection of nerve signals through vasculature. The company plans to commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval. The technology aims to commercialize the Autonomix Sensing and RF Ablation System for treating pancreatic cancer pain in the United States.

Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment technologies, has announced its participation in the Virtual Investor Closing Bell Series scheduled for Wednesday, January 22, 2025, at 4:00 PM ET.

During the event, CEO Brad Hauser will deliver a corporate overview and business outlook. The format includes a moderated discussion with a live Q&A session where investors can submit questions. The company will address as many queries as time permits.

The presentation will be accessible through a live video webcast on the Events page in the Investors section of autonomix.com. A replay will be available two hours after the live event and remain accessible for 90 days.

Autonomix Medical (NASDAQ: AMIX) announced the acceptance of its abstract for poster presentation at the Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting, scheduled for January 30 – February 3, 2025, in Las Vegas. The abstract, titled 'Ablation of the Celiac Ganglia for Treatment of Pancreatic Cancer Pain: An Interim Analysis of the First Five Lead-In Patients,' will be presented by the company's Chief Medical Officer, Dr. Rob Schwartz.

The presentation at SIO, a non-profit organization focused on advancing interventional oncology as a key cancer therapy approach, represents an opportunity to showcase the company's progress in developing treatments for diseases involving the nervous system.

Autonomix Medical (NASDAQ: AMIX) has been granted U.S. patent 12,064,256 covering technology for treating cancerous tumors and cancer-related pain. The company's growing patent portfolio includes over 80 issued patents and 40+ pending applications. A preclinical mouse study showed statistically significant reductions in both metastases and tumor mass through targeted nerve ablation.

The company's proprietary catheter-based technology features a microchip sensing array antenna with up to 3,000 times greater sensitivity than current technologies. Initially focusing on pancreatic cancer-related pain, Autonomix's platform combines nerve detection and RF ablation capabilities for precise treatment. The company is currently conducting a proof-of-concept human clinical trial focused on pain reduction.

Autonomix Medical (NASDAQ: AMIX) has published a new CEO Corner segment on its website. The segment features CEO Brad Hauser's reflections on the company's progress throughout the past year and provides insights into future plans. Autonomix is a medical device company that focuses on developing innovative technologies for diagnosing and treating diseases of the nervous system.

Autonomix Medical (NASDAQ: AMIX) has appointed Julie Manchester as Vice President of Regulatory Affairs and Quality, strengthening its team ahead of planned FDA approval initiatives. The company, which recently completed animal testing and design lock for its RF technology, remains on track to submit an Investigational Device Exemption (IDE) and commence a pivotal clinical trial in 2025 to support a De Novo FDA application.

Manchester brings over 15 years of quality and regulatory experience in medical devices and related industries. The company granted her an inducement stock option to purchase 19,500 shares, vesting over four years. Autonomix continues to make progress in its proof-of-concept clinical trial for treating pancreatic cancer pain, reporting positive patient outcomes.

Autonomix Medical (NASDAQ: AMIX) has achieved design lock for its radio frequency (RF) ablation catheter following successful animal testing. The company's first-in-class catheter-based technology features a microchip sensing array antenna that can detect neural signals with up to 3,000 times greater sensitivity than current technologies.

The company plans to submit an Investigational Device Exemption (IDE) and commence a pivotal clinical trial in the second half of 2025 to support a De Novo application for FDA approval. The technology aims to revolutionize chronic pain treatment, particularly for pancreatic cancer patients, by offering a precision-guided approach to sense, treat, and verify nerve ablation, potentially replacing current treatments like opioids and invasive ethanol injections.

Autonomix Medical (NASDAQ: AMIX) has closed its previously announced underwritten public offering, raising $10.0 million in gross proceeds. The offering included 615,500 common stock units and 917,596 pre-funded warrant units, priced at $6.54 and $6.539 respectively. Each unit contained one share (or pre-funded warrant) and one Series A Warrant with a five-year term and $6.54 exercise price. The offering included a partial exercise of the over-allotment option. Ladenburg Thalmann & Co. acted as sole bookrunner. Proceeds will fund clinical trials, research and development, intellectual property development, and working capital.

Autonomix Medical announced the pricing of an underwritten public offering expected to raise $9.0 million in gross proceeds. The offering consists of 1,376,287 common stock units priced at $6.54 per unit. Each unit includes one share of common stock (or pre-funded warrant) and one Series A warrant exercisable at $6.54 with a five-year term. The company granted the underwriter a 45-day option to purchase up to 15% additional shares and warrants. Proceeds will fund clinical trials, research and development, intellectual property development, and working capital. Ladenburg Thalmann & Co. is acting as sole bookrunning manager.